BioMarin Announces Governance Enhancements and Value Creation Initiatives
Board Approves Appointment of Three New Independent Directors
Company Establishes Strategic and Operating Review Committee of the Board
BioMarin Enters into Cooperation and Information Sharing Agreements with Elliott
Related news for (BMRN)
- BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET
- BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress
- BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany